A detailed history of China Universal Asset Management Co., Ltd. transactions in Cytokinetics Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 19,770 shares of CYTK stock, worth $1.08 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
19,770
Previous 19,770 -0.0%
Holding current value
$1.08 Million
Previous $1.39 Million -0.0%
% of portfolio
0.18%
Previous 0.18%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$63.75 - $108.06 $537,348 - $910,837
8,429 Added 74.32%
19,770 $1.39 Million
Q4 2023

May 21, 2024

SELL
$26.88 - $83.49 $226,571 - $703,737
-8,429 Reduced 42.64%
11,341 $946,000
Q4 2023

Jan 23, 2024

BUY
$26.88 - $83.49 $238,640 - $741,224
8,878 Added 360.45%
11,341 $947,000
Q3 2023

May 21, 2024

BUY
$29.46 - $36.61 $35,617 - $44,261
1,209 Added 96.41%
2,463 $72,000
Q3 2023

Oct 30, 2023

BUY
$29.46 - $36.61 $35,617 - $44,261
1,209 Added 96.41%
2,463 $73,000
Q2 2023

May 21, 2024

SELL
$32.62 - $40.75 $913 - $1,141
-28 Reduced 2.18%
1,254 $40,000
Q2 2023

Jul 27, 2023

SELL
$32.62 - $40.75 $913 - $1,141
-28 Reduced 2.18%
1,254 $41,000
Q1 2023

May 21, 2024

BUY
$33.36 - $45.71 $10,708 - $14,672
321 Added 33.4%
1,282 $45,000
Q1 2023

Apr 27, 2023

BUY
$33.36 - $45.71 $10,708 - $14,672
321 Added 33.4%
1,282 $45,000
Q4 2022

May 21, 2024

SELL
$35.77 - $51.11 $672,797 - $961,327
-18,809 Reduced 95.14%
961 $44,000
Q4 2022

Jan 31, 2023

SELL
$35.77 - $51.11 $968,901 - $1.38 Million
-27,087 Reduced 96.57%
961 $44,000
Q3 2022

Oct 21, 2022

BUY
$38.54 - $54.52 $1.08 Million - $1.53 Million
28,048 New
28,048 $1.36 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $5.12B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.